MARKET

EDIT

EDIT

Editas Medicine Inc
NASDAQ
5.52
-0.10
-1.78%
Closed 19:51 05/20 EDT
OPEN
5.68
PREV CLOSE
5.62
HIGH
5.72
LOW
5.49
VOLUME
1.15M
TURNOVER
0
52 WEEK HIGH
11.91
52 WEEK LOW
4.910
MARKET CAP
453.95M
P/E (TTM)
-2.6251
1D
5D
1M
3M
1Y
5Y
Editas Medicine: Promising Milestone Achieved But Be Patient
Seeking Alpha · 5d ago
Editas Medicine To Present Clinical Data From The RUBY And EdiTHAL Trials Of Reni-cel At The EHA 2024 Congress In June
Editas Medicine to present clinical data from RUBY and EdiTHAL trials of renizgamglogene autogedtemcel at European Hematology Association Hybrid Congress in 2024. The company is a clinical-stage gene editing company. Two abstracts will be presented at the EHA Hybrid Congress.
Benzinga · 6d ago
Weekly Report: what happened at EDIT last week (0506-0510)?
Weekly Report · 05/13 09:11
Analysts Have Lowered Expectations For Editas Medicine, Inc. (NASDAQ:EDIT) After Its Latest Results
Editas Medicine, Inc. Reported disappointing quarterly earnings last week. Revenues of US$ missed forecasts by 84%. The company's per-share losses are expected to explode, reaching US$ per share in 2024. The company is expected to perform substantially worse than the wider industry. We look at the most recent consensus estimates for the company.
Simply Wall St · 05/12 12:16
Editas Medicine Reports Presentation Of Preclinical Data Demonstrating Several In Vivo Capabilities Towards Developing Transformative In Vivo Gene Editing Medicines
Benzinga · 05/10 10:06
Buy Rating Affirmed for Editas Medicine Amid Promising CRISPR Pipeline and Growth Potential
TipRanks · 05/10 05:41
Editas Medicine Hold Rating: Balancing Pipeline Potential with Financial and Legal Prudence
TipRanks · 05/10 05:32
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
Barchart · 05/10 05:00
More
About EDIT
Editas Medicine, Inc. is a clinical-stage genome editing company. The Company is focused on developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology. CRISPR uses a protein- ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide ribonucleic acid (RNA) molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. It is engaged in the development of vivo administered gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body. Its lead program, reni-cel, is an experimental ex vivo gene-edited medicine to treat sickle cell disease (SCD), a severe inherited blood disease that causes premature death, and transfusion-dependent beta thalassemia (TDT).

Webull offers Editas Medicine Inc stock information, including NASDAQ: EDIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDIT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EDIT stock methods without spending real money on the virtual paper trading platform.